Final pass
Decision checklist: pause, compare, decide
The short version
As of September 2026, thymosin alpha-1 has no FDA-approved U.S. product, and FDA reviewers found the evidence insufficient for every proposed use they examined.
That leaves more work for the person considering an offer: verify the care, the preparation, the evidence, the unknowns, and the full price.
Move on from the offer
A compounded product described as FDA approved is being described falsely.
FDA has told sellers in writing that a product labeled “for research” but sold for people to use is an unapproved drug. Selling it across state lines breaks federal law.
- No clinician can be identified.
- No pharmacy is named.
- A prescription is not required.
- Questions are met with pressure or promises.
Pause and ask again
- The condition being treated is vague.
- The evidence answer is only “people use it.”
- The exact preparation is unclear.
- The price leaves out medicine, tests, shipping, or follow-up.
- No one owns the follow-up plan.
Compare only when the basics are clear
Write the answers in one place: clinician, licence, condition, evidence, preparation, pharmacy, known harms, open questions, total cost, and follow-up. A blank is useful information.
The final choice belongs in a conversation that can use your health history and answer your questions.